Moonwalk Biosciences
Moonwalk Biosciences is an early-stage, pre-clinical therapeutics company based in South San Francisco, California, with an additional office in San Diego. Founded in 2022, the company focuses on developing precision epigenetic medicines to address complex diseases by targeting the epigenome without altering the DNA sequence. The company was co-founded by CRISPR pioneer Feng Zhang and former Illumina CTO Alex Aravanis, who currently serves as CEO. The company operates an integrated epigenetic discovery and engineering platform that includes EpiRead, which maps the epigenome at single-cell resolution, and EpiWrite, which utilizes CRISPR-based tools for precise epigenetic modifications. Moonwalk is developing a pipeline of therapeutics aimed at treating obesity, cardiometabolic diseases, and liver diseases, using small molecules and oligonucleotide therapeutics to create tailored treatment options. The company actively engages with the scientific community to share its findings and advance research in epigenetic biology and AI-driven drug discovery.